Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Fig. 2

The measured inflammatory biomarkers at baseline and week 26 revealed a significant reduction in all IL-6, IL-1β, and Hs-CRP in empagliflozin group compared to placebo (P < 0.05). IL-6 Interleukin 6, IL-1 β: Interleukin 1-beta, Hs-CRP: High sensitivity C-reactive protein

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us